Selected stock price target news of the day - September 5th, 2024

By: Matthew Otto

Ascendis Pharma Reports Lower Q2 Revenue and Revises Full-Year SKYTROFA Guidance

Ascendis Pharma held its second quarter 2024 earnings call, reporting a net loss per share (EPS) of $(2.06), which was $0.60 worse than the analyst estimate of $(1.46). Revenue for the quarter was $39 million, below the consensus estimate of $91 million.

In terms of financial guidance, Ascendis revised its full-year 2024 SKYTROFA revenue expectations to $240 million to $261 million, down from the previous range of $349 million to $371 million, and below the estimated $382 million. For the second quarter, SKYTROFA generated $28 million in revenue, representing a 27% year-over-year decrease, attributed to higher sales deductions.

Ascendis closed the quarter with $284 million in cash, cash equivalents, and marketable securities and secured an additional $150 million in funding through a synthetic royalty agreement with Royalty Pharma

Analyst Ratings Adjust Amid Q2 Revenue Miss and Revised Guidance

Oppenheimer analyst Leland Gershell upgraded from Perform to Outperform and set a $180 price target.
Citigroup analyst David Lebowitz maintained a Buy rating but lowered the price target from $193 to $178.
JP Morgan analyst Jessica Fye retained an Overweight rating, though reduced the price target from $174 to $165.
TD Cowen analyst Yaron Werber kept a Buy rating yet decreased the price target from $175 to $157.
BofA Securities analyst Tazeen Ahmad maintained a Buy rating and raised the price target from $165 to $175.
Wells Fargo analyst Derek Archila kept an Overweight rating, however adjusted the price target down from $277 to $264.
Cantor Fitzgerald analyst Li Watsek continued an Overweight rating, while trimming the price target from $173 to $170.

Which Analyst has the best track record to show on ASND?

Analyst Jessica Fye (JPMORGAN) currently has the highest performing score on ASND with 14/17 (82.35%) price target fulfillment ratio. Her price targets carry an average of $37 (27.01%) potential upside. Ascendis Pharma stock price reaches these price targets on average within 120 days.

Dollar Tree Lowers Full-Year Guidance After Disappointing Q2 Results

Dollar Tree now expects its consolidated net sales for the fiscal year 2025 to range between $30.6 billion and $30.9 billion, a reduction from the previous estimate of $31.19 billion. Adjusted earnings per share (EPS) are projected to be between $5.20 and $5.60, compared to the consensus estimate of $6.55. The downward revision reflects ongoing sales struggles and increased costs related to store conversions and legal claims.

For the second quarter ended August 3, Dollar Tree reported an EPS of $0.67, falling short of the analyst estimate of $1.06, and revenue of $7.37 billion, below the consensus of $7.5 billion.

Same-store sales rose by 0.7% during the quarter, with Dollar Tree stores up by 1.3% and Family Dollar experiencing a 0.1% decline. In March, Dollar Tree announced plans to close approximately 1,000 Family Dollar stores and is considering selling the brand.

Analysts Cut Targets Following Q2 Results and Revised Guidance

Evercore ISI Group analyst Greg Melich maintained a rating of In-Line and lowered the price target from $128 to $78.
Morgan Stanley analyst Simeon Gutman kept a rating of Equal-Weight but reduced the price target from $130 to $80.
Loop Capital analyst Anthony Chukumba downgraded from Buy to Hold and set a new price target of $65.
Keybanc analyst Bradley Thomas maintained an Overweight rating, yet lowered the price target from $145 to $84.
Piper Sandler analyst Peter Keith remained Neutral but decreased the price target from $112 to $67.
BMO Capital analyst Kelly Bania downgraded from Outperform to Market Perform and adjusted the price target from $130 to $68.
JP Morgan analyst Matthew Boss downgraded from Overweight to Neutral and the price target from $111 to $70.

Which Analyst has the best track record to show on DLTR?

Analyst Joseph Feldman (TELSEY ADVISORY) currently has the highest performing score on DLTR with 8/26 (30.77%) price target fulfillment ratio. His price targets carry an average of $35.51 (42.03%) potential upside. Dollar Tree stock price reaches these price targets on average within 105 days.

Couchbase Falls Short of Revenue and ARR Expectations Despite Strong Q2 Performance

Couchbase reported results for the second quarter of 2025, with an earnings per share (EPS) of ($0.06), surpassing the analyst estimate of ($0.09) by $0.03. Achieved revenue of $51.6 million for the quarter, exceeding the consensus estimate of $51.11 million. This revenue figure represents a 20% increase year-over-year.

The annual recurring revenue (ARR) stood at $214 million, reflecting an 18% increase from the previous year and a 19% rise in constant currency. However, the non-GAAP operating loss was $4.1 million, resulting in an 8% operating margin that was above the company’s guidance range.

Couchbase’s Capella platform also demonstrated its performance, with Capella ARR reaching $28.9 million, up 20% and representing 13.5% of total ARR. Capella’s customer base grew by 37 during the quarter.

Looking ahead, Couchbase has provided guidance for the third quarter of 2025, forecasting revenue between $50.3 million and $51.1 million, which is below the consensus estimate of $50.687 million. For the full fiscal year 2025, Couchbase anticipates revenue to be in the range of $205.1 million to $209.1 million, compared to the consensus estimate of $207.3 million.

Analysts Slash Price Targets After Q2 Performance

UBS analyst Austin Dietz maintained a Neutral rating, but lowered the price target from $24 to $19.
Morgan Stanley analyst Sanjit Singh kept an Equal-Weight rating, but reduced the price target from $29 to $27.
Stifel analyst Brad Reback retained a Buy rating and revised the price target from $25 to $20.
Baird analyst Rob Oliver maintained an Outperform rating while adjusting the price target from $32 to $27.
Needham analyst Mike Cikos reaffirmed a Buy rating and a $22 price target.
Piper Sandler analyst Brent Bracelin kept an Overweight rating, but lowered the price target from $22 to $21.

Which Analyst has the best track record to show on BASE?

Analyst Kash Rangan (GOLDMAN SACHS) currently has the highest performing score on BASE with 3/6 (50%) price target fulfillment ratio. His price targets carry an average of $-0.41 (-2.23%) potential downside. Couchbase stock price reaches these price targets on average within 59 days.